FY2024 EPS Estimates for Journey Medical Raised by Analyst

Journey Medical Co. (NASDAQ:DERM - Free Report) - Equities research analysts at Roth Capital increased their FY2024 earnings per share estimates for shares of Journey Medical in a research report issued to clients and investors on Monday, November 4th. Roth Capital analyst J. Wittes now forecasts that the company will earn ($0.93) per share for the year, up from their prior estimate of ($0.96). The consensus estimate for Journey Medical's current full-year earnings is ($1.04) per share. Roth Capital also issued estimates for Journey Medical's Q4 2024 earnings at ($0.12) EPS.

Journey Medical (NASDAQ:DERM - Get Free Report) last announced its earnings results on Monday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.03). Journey Medical had a net margin of 1.09% and a return on equity of 5.44%. The firm had revenue of $14.86 million during the quarter, compared to analyst estimates of $13.81 million. During the same period in the prior year, the business posted ($0.46) EPS.

Several other equities research analysts have also issued reports on DERM. Rodman & Renshaw began coverage on shares of Journey Medical in a research note on Thursday, August 22nd. They issued a "buy" rating and a $9.00 price target on the stock. Lake Street Capital began coverage on Journey Medical in a research report on Friday, September 6th. They issued a "buy" rating and a $9.00 target price on the stock. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $9.38.

Journey Medical Stock Up 5.0 %

Shares of NASDAQ DERM traded up $0.27 during midday trading on Thursday, reaching $5.71. The company's stock had a trading volume of 134,041 shares, compared to its average volume of 122,024. The stock has a 50 day simple moving average of $5.55 and a 200-day simple moving average of $4.97. The company has a current ratio of 1.36, a quick ratio of 1.08 and a debt-to-equity ratio of 1.75. The stock has a market capitalization of $118.37 million, a price-to-earnings ratio of -285.50 and a beta of 0.92. Journey Medical has a fifty-two week low of $2.85 and a fifty-two week high of $8.11.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. TMD Wealth Management LLC bought a new position in Journey Medical during the second quarter worth about $65,000. Nwam LLC bought a new position in Journey Medical during the first quarter worth $41,000. ORG Wealth Partners LLC acquired a new position in shares of Journey Medical in the third quarter valued at $110,000. Heron Bay Capital Management bought a new position in shares of Journey Medical in the first quarter valued at about $124,000. Finally, Rosalind Advisors Inc. acquired a new stake in shares of Journey Medical during the 2nd quarter worth about $644,000. 7.25% of the stock is currently owned by institutional investors and hedge funds.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.